Is Symrise (XTRA:SY1) Expensive On Flat Half Year Earnings?
Symrise (XTRA:SY1) has drawn attention after reporting half year 2026 earnings, with sales of €2,539.34m and net income of €264.91m, both slightly below the prior year period.
See our latest analysis for Symrise.
Symrise shares trade at €90.96, with a 1-day share price return of 1.86% and a 90-day share price return of 19.84%. The 5-year total shareholder return of 22.76% is still down overall, which suggests that recent momentum has picked up after a weaker longer run.
If Symrise’s recent move has you reassessing your watchlist, this could be a good moment to broaden your search with 104 top founder-led companies
Symrise just reported flat earnings and a sharp rebound in the share price, which puts today’s buyers in a different risk profile from those who bought earlier in the year. Does that recent strength still leave enough upside on the table?
Most Popular Narrative: 21.3% Overvalued
The most followed narrative for Symrise pegs fair value at €75, which sits well below the latest close at €90.96. That gap is built on relatively cautious assumptions about growth and profitability.
Although Symrise is executing on a sizable cost saving and efficiency agenda, the increasing reliance on self help to lift margins risks reaching a ceiling if raw material and logistics markets tighten again. This could cap future EBITDA expansion and slow earnings growth.
Want to see what is really baked into that €75 fair value? The narrative leans on steady revenue growth, rising margins and a lower future earnings multiple. You may be curious which specific profit and valuation assumptions pull the current share price above that line.
The narrative uses a 5.64% discount rate and builds a path where earnings, margins and the valuation multiple all shift over time. It also sets Symrise’s fair value below both the current share price and parts of the analyst target range, which offers a clear benchmark to test against your own expectations.
Result: Fair Value of €75 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Symrise could still surprise on the upside if the ONE SYM Transformation delivers stronger margin gains, or if health focused product demand proves more resilient than cautious forecasts assume.
Find out about the key risks to this Symrise narrative.
Another View on Symrise’s Value
The first narrative argues Symrise looks expensive around €90.96 compared with a €75 fair value, based on cautious growth and margin assumptions. Our DCF model points the other way and puts fair value closer to €148.74, which is about 38.8% above the current price.
That gap between analyst narrative and discounted cash flow raises a simple question for you as an investor: Are current expectations too low on future cash generation, or is the DCF model giving Symrise more credit than it should for execution and capital discipline?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Symrise for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 243 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given the mixed messages around Symrise today, it makes sense to move quickly, review the underlying data for yourself and decide where you stand. To help weigh both sides of the story, take a look at the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Symrise?
If Symrise has sharpened your focus, do not stop with a single stock. Use curated stock lists to spot opportunities that match your style before others move first.
- Target potential mispricing by reviewing companies highlighted in the 243 high quality undervalued stocks and see which stocks line up with your expectations.
- Prioritise resilience by scanning the solid balance sheet and fundamentals stocks screener (420 results) that filters for companies with stronger finances and steadier foundations.
- Spot tomorrow's potential standouts by exploring the screener containing 549 high quality undiscovered gems before they attract wider market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com